Granted Patent
B2
US 12,723,095 · App. 18/148,813 · Granted Sep 1, 2026
Methods of treating cancer using binding molecules that bind CD137 and PD-L1
Inventors:
Cecilia Anna Wilhelmina Geuijen (Utrecht, NL); Mark Throsby (Utrecht, NL); Cornelis Adriaan De Kruif (Utrecht, NL); Rinse Klooster (Utrecht, NL); Paulus Johannes Tacken (Utrecht, NL); Ton Logtenberg (Utrecht, NL)
Assignee:
MERUS N.V.
C07K16/2878C07K16/2827A61K2039/505C07K2317/24C07K2317/31C07K2317/35C07K2317/55C07K2317/732C07K2317/734C07K2317/75C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.
Claims (20)
1 . A method for treating cancer in an individual, wherein the individual has PD-L1-expressing cancer cells or neoplastic cells, the method comprising administering to the individual in need thereof an antibody that comprises:
a first antigen binding site that binds an extracellular part of CD137 and that comprises a heavy chain variable region comprising the complementarity determining regions (CDR) CDR1, CDR2, and CDR3 of SEQ ID NO: 129 according to Kabat numbering, and
a second antigen binding site that binds an extracellular part of PD-L1 and that comprises a heavy chain variable region that comprises the CDR1, CDR2, and CDR3 of SEQ ID NO: 212 according to Kabat numbering;
wherein the first and second antigen binding sites each comprise a common light chain comprising the CDR1, CDR2 and CDR3 of SEQ ID NO: 106 according to IMGT numbering.
2 . The method of claim 1 , wherein the cancer is an adenocarcinoma.
3 . The method of claim 1 , wherein the cancer is colorectal cancer; pancreatic cancer; lung cancer; breast cancer; liver cancer; prostate cancer; ovarian cancer; cervical cancer; endometrial cancer; head and neck cancer; melanoma; testis cancer; urothelial cancer; renal cancer; stomach cancer; or carcinoid cancer.
4 . The method of claim 1 , wherein the cancer is colorectal cancer; pancreatic cancer; lung cancer; breast cancer; liver cancer; prostate cancer; ovarian cancer; cervical cancer; endometrial cancer; head and neck cancer; or melanoma.
5 . The method of claim 1 , wherein the cancer is colorectal cancer; pancreatic cancer; lung cancer; breast cancer; or liver cancer.
6 . The method of claim 1 , wherein the cancer is a gastrointestinal cancer.
7 . The method of claim 1 , wherein the cancer is colorectal cancer.
8 . The method of claim 1 , wherein the antibody is a bispecific antibody.
9 . The method of claim 1 , wherein the antibody is an IgG.
10 . The method of claim 1 , wherein the antibody is an IgG1, IgG2, IgG3, or IgG4.
11 . The method of claim 1 , wherein the antibody is a human antibody.
12 . The method of claim 1 , wherein the antibody comprises a first heavy chain variable region that is at least 90% identical to SEQ ID NO: 129 and a second heavy chain variable region that is at least 90% identical to SEQ ID NO: 212.
13 . The method of claim 1 , wherein the antibody comprises the first antigen binding site comprising a first heavy chain variable region comprising SEQ ID NO: 129 and the second antigen binding site comprises a second heavy chain variable region comprising SEQ ID NO: 212.
14 . The method of claim 1 , wherein the antibody comprises the first antigen binding site comprising a first heavy chain variable region comprising SEQ ID NO: 129.
15 . The method of claim 1 , wherein the antibody comprises the second antigen binding site comprising a second heavy chain variable region comprising SEQ ID NO: 212.
16 . The method of claim 1 , wherein the first antigen binding site comprises a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 129; wherein the second antigen binding site comprises a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 212; and wherein the first and second antigen binding site comprise a common light chain comprising the CDR1 of SEQ ID NO: 256, a CDR2 comprising the amino acid sequence AAS, and the CDR3 of SEQ ID NO: 257.
17 . The method of claim 1 , wherein the first antigen binding site comprises a first heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 129 and the second antigen binding site comprises a second heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 212; and wherein the first and second antigen binding sites each comprise a common light chain variable region comprising the amino acid sequence of SEQ ID NO: 106.
Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS
Recorded Jan 30, 2026
From: MERUS B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 074562/0322 →
SECURITY INTEREST
Recorded Jan 29, 2026
From: MERUS B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 074532/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 7, 2024
From: GEUIJEN, CECILIA ANNA WILHELMINA; THROSBY, MARK; DE KRUIF, CORNELIS ADRIAAN; KLOOSTER, RINSE; TACKEN, PAULUS JOHANNES; LOGTENBERG, TON
To: MERUS N.V.
Reel/Frame 069182/0617 →
Priority Claims (1)
EP 16190499
· Sep 23, 2016
· regional
Continuity (2)
References Cited (139)
US 8337850B2
· Ahrens et al.
· 2012
[cited by applicant]
US 9248181B2
· De Kruif et al.
· 2016
[cited by applicant]
US 9358286B2
· De Kruif et al.
· 2016
[cited by applicant]
US 20130336971A9
· De Kruif et al.
· 2013
[cited by applicant]
US 20150190506A1
· Cheung et al.
· 2015
[cited by applicant]
US 20150307620A1
· Vella et al.
· 2015
[cited by applicant]
EP 3130606A1
· 2017
[cited by applicant]
EP 3778648A1
· 2021
[cited by applicant]
TW 201946655A
· 2019
[cited by applicant]
WO WO0114424A2
· 2001
[cited by applicant]
WO WO0156603A1
· 2001
[cited by applicant]
WO WO2004009618A2
· 2004
[cited by applicant]
WO WO2005035584A1
· 2005
[cited by applicant]
WO WO2006091209A2
· 2006
[cited by applicant]
WO WO2008027236A2
· 2008
[cited by applicant]
WO WO2009126920A2
· 2009
[cited by applicant]
WO WO2009157771A2
· 2009
[cited by applicant]
WO WO2010077634A1
· 2010
[cited by applicant]
WO WO2010108127A1
· 2010
[cited by applicant]
WO WO2013157953A1
· 2013
[cited by applicant]
WO WO2013157954A1
· 2013
[cited by applicant]
WO WO2017060144A1
· 2014
[cited by applicant]
WO WO2014116846A2
· 2014
[cited by applicant]
WO WO2014163684A1
· 2014
[cited by applicant]
WO WO2015063339A1
· 2015
[cited by applicant]
WO WO2015095423A2
· 2015
[cited by applicant]
WO WO2015119923A1
· 2015
[cited by applicant]
WO WO2015156268A1
· 2015
[cited by applicant]
WO WO2016110584A1
· 2016
[cited by applicant]
WO WO2016111645A1
· 2016
[cited by applicant]
WO WO2016115274A1
· 2016
[cited by applicant]
WO WO2016145085A2
· 2016
[cited by applicant]
WO WO2016164480A1
· 2016
[cited by applicant]
WO WO2016185016A1
· 2016
[cited by applicant]
WO WO2016196228A1
· 2016
[cited by applicant]
WO WO2016207273A2
· 2016
[cited by applicant]
WO WO2017055398A2
· 2017
[cited by applicant]
WO WO2017096179A1
· 2017
[cited by applicant]
WO WO2017123650A2
· 2017
[cited by applicant]
WO WO2017123673A2
· 2017
[cited by applicant]
WO WO2017182672A1
· 2017
[cited by applicant]
WO WO2017193032A2
· 2017
[cited by applicant]
WO WO2017205738A1
· 2017
[cited by applicant]
WO WO2018045110A1
· 2018
[cited by applicant]
WO WO2018056821A1
· 2018
[cited by applicant]
Lasaro et al., Pembrolizumab and ipilimumab reduce human RKO colon carcinoma tumor growth in HLA matched CD34-NSG humanized mice, Canc. Res. 75(14_Suppl):2215, doi.org/10.1158/1538-7445.AM2016-2215, Jul. 2016.
[cited by examiner]
Akbay, E. A., et al., “Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors,” Cancer Discov, 3(12): 1355-1363, American Association for Cancer Research, United States (2013).
[cited by applicant]
Almagro, C., and Fransson, J., “Humanization of antibodies,”
[cited by applicant]
Arch, R. H., and Thompson, C. B., “4-1BB and O×40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor
[cited by applicant]
Armour, KL. et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,”
[cited by applicant]
Arndt C., et al., “Costimulation Improves The Killing Capability of T Cells Redirected To Tumor Cells Expressing Low Levels Of CD33: Description Of A Novel Modular Targeting System,”
[cited by applicant]
Bakker, A.B., et al., “C-Type Lectin-Like Molecule-1: A Novel Myeloid Cell Surface Marker Associated With Acute Myeloid Leukemia,”
[cited by applicant]
Bernstein, M. B., et al., “Radiation-induced modulation of costimulatory and coinhibitory T- cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions,” Cancer Biother …
[cited by applicant]
Bertram, E.M., et al., “Role of T cell costimulation in anti-viral immunity,”
[cited by applicant]
Boland, J. M., et al., “Tumor B7-H1 And B7-H3 Expression In Squamous Cell Carcinoma Of The Lung,”
[cited by applicant]
Brandt, C.S., et al., “The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans,”
[cited by applicant]
Chen, C.H., et al., “Dendritic-cell-associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production,”
[cited by applicant]
Compaan, D.M., and Hymowitz, S.G. The Crystal Structure Of The Costimulatory OX40-OX40L Complex,
[cited by applicant]
Davidson, E. and Doranz, B.J., “A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitope.,”
[cited by applicant]
De Haard, H.J., et al., “A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rapid Isolation And Kinetic Analysis Of High Affinity Antibodies,”
[cited by applicant]
Dong, H., et al., “Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion,”
[cited by applicant]
Fisher, T.S., et al., “Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity,”
[cited by applicant]
Ghosh, R., et al., “Trastuzumab Has Preferential Activity Against Breast Cancers Driven By HER2 Homodimer,”
[cited by applicant]
Gunasekaran, K., et al., “Enhancing Antibody Fc Heterodimer Formation Through Electrostatic Steering Effects: Applications To Bispecific Molecules And Monovalent Igg,”,
[cited by applicant]
Han, Y., et al., KLRL1, a novel killer cell lectinlike receptor, inhibits natural killer cell cytotoxicity,
[cited by applicant]
Hinner, M. J., et al., “Costimulatory T cell engagement via a novel bispecific anti-CD137 / anti-Her2 protein,”
[cited by applicant]
Hinner, M. J., et al., “Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-Her2 protein based on Anticalin® technology,” Pieris Pharmaceuticals, CRI 2015, New York Sep. 18, 2015.
[cited by applicant]
Idusogie, E.E., et al., “Mapping of the Clq binding site on rituxan, a chimeric antibody with a human IgG1 Fc,”
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/NL2017/050634, European Patent Office, Netherlands, mailed Feb. 19, 2018, 37 pages.
[cited by applicant]
Janakiram, M., et al., “Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein,”
[cited by applicant]
Jaron-Mendelson, M., et al., “Dimerization Of Nkp46 Receptor Is Essential For Nkp46-Mediated Lysis: Characterization Of The Dimerization Site By Epitope Mapping,”
[cited by applicant]
Koide, A., et al., “The Fibronectin Type Iii Domain As A Scaffold For Novel Binding Proteins,”
[cited by applicant]
Kraan, J. et al., “Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells,”
[cited by applicant]
Labrijn, A.F. et al., “Therapeutic Igg4 Antibodies Engage In Fab-Arm Exchange With Endogenous Human Igg4 In Vivo,”
[cited by applicant]
Lu, D., et al. “Abstract 572: A novel anti-PDL1 x anti-VEGFR1 bispecific antibody for enhanced antitumor immunity,” Proceedings: AACR 107th Annual Meeting 2016; Apr. 16-20, 2016; New Orleans, LA, retrieved from at https…
[cited by applicant]
Makkouk, A., et al., “Rationale for anti-CD137 cancer immunotherapy,”
[cited by applicant]
Marks, J.D. et al., “By-passing immunization. Human antibodies from V-gene libraries displayed on phage,”
[cited by applicant]
Marshall, A.S. et al., “Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes,”
[cited by applicant]
Mcnamara, J.O. et al., “Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice,”
[cited by applicant]
Melero, I. et al., “Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination,”
[cited by applicant]
Melero, I et al., “Agonist antibodies to TNFR molecules that costimulate T and NK cells,”
[cited by applicant]
Merchant, A.M. et al., “An efficient route to human bispecific IgG,”
[cited by applicant]
Michel, J., et al., “A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis,”
[cited by applicant]
Morrison, S.L., “Two heads are better than one,”
[cited by applicant]
Moshaver, B. et al., “Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia,”
[cited by applicant]
Nissim, A. et al., “Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents,” The
[cited by applicant]
Pollok, K. E., et al., “Inducible T cell antigen 4-1BB. Analysis of expression and function,”
[cited by applicant]
Pulko, V. et al., “B7-H1 expressed by activated CD8 T cells is essential for their survival,”
[cited by applicant]
Reyes-Moreno, C., et al., “CD40/CD40 homodimers are required for CD40-induced phosphatidylinositol 3-kinase-dependent expression of B7.2 by human B lymphocytes,”
[cited by applicant]
Ross, J.S., et al., “A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma,”
[cited by applicant]
Sanmamed, M.F., et al., “Nivolumab And 20H4.9 Enhance Antitumor Activity Of Human T Lymphocytes Engrafted in Rag2
[cited by applicant]
Schaefer, G., et al., “A Two-In-One Antibody Against HER3 And EGFR Has Superior Inhibitory Activity Compared With Monospecific Antibodies,”
[cited by applicant]
Schwarz, H., “Biological activities of reverse signal transduction through C137 ligand,”
[cited by applicant]
Shao, Z., et al., “Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications,”
[cited by applicant]
Shao, Z., and Schwarz, H., “CD137 ligand, a member of the tumor necrosis factor family, regulates immune responses via reverse signal transduction.,”
[cited by applicant]
Sharma, P., et al., “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,”
[cited by applicant]
Simon, H. U. “Evidence for a pro-apoptotic function of CD137 in granulocytes,”
[cited by applicant]
Sharpe, A.H., and Freeman, G., “The B7-CD28 Superfamily,”
[cited by applicant]
Shields, R.L., et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,”
[cited by applicant]
Sznol, M., and Chen, L., “Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer,”
[cited by applicant]
Thompson, R. H., et al., “Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma,”
[cited by applicant]
Tumeh, P. C., et al., “PD-1 blockade induces responses by inhibiting adaptive immune resistance,”
[cited by applicant]
Van Rhenen, A., et al., “The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells,”
[cited by applicant]
Velcheti, V., et al., “Programmed death ligand-1 expression in non-small cell lung cancer,”
[cited by applicant]
Vereb, G., et al., “Dynamic, yet structured: The cell membrane three decades after the Singer-Nicolson model,”
[cited by applicant]
Vezys, V., et al., “4-1BB Signaling Synergizes with Programmed Death Ligand 1 Blockade To Augment CD8 T Cell Responses during Chronic Viral Infection,”
[cited by applicant]
Vinay, D. S., and Kwon, B. S., “4-1BB signaling beyond T cells,”
[cited by applicant]
Wu, C., et al., “Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin,”
[cited by applicant]
Wolf B., et al., “A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans,”
[cited by applicant]
Wölfl, M., and Greenberg, P.D., “Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells,”
[cited by applicant]
Won, E. Y., et al., “The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily,”
[cited by applicant]
Xu, L. et al., “Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts,”
[cited by applicant]
Yarden, Y., and Pines, G., “The ERBB network: at last, cancer therapy meets systems biology,”
[cited by applicant]
Yi, L., et al., “Human and mouse CD137 have predominantly different binding CRDs to their respective ligands,”
[cited by applicant]
Zhang, F., et al., “Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade,”
[cited by applicant]
Zhao, Y., et al., “Targeting 4-1BB (CD137) to enhance CD8 T cell responses with poxviruses and viral antigens,”
[cited by applicant]
Zhou, G., et al., “Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas,”
[cited by applicant]
Kondo, A., et al., Interferon-? And tumor necrosis factor-a induce an immunoinhibitory molecule, B7-H1, via nuclear factor-?B activation in blasts in myelodysplastic syndromes.
[cited by applicant]
Dickopf, S., et al., “Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies,” Computational and Structural Biotechnology Journal 18:1221-1227, Elsevier, Netherlands (202…
[cited by applicant]
Geuijen, C., et al., “A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade,” Nat Commun 12(1):4445, Nature Publishing Group, United King…
[cited by applicant]
Dondelinger, M., et al., “Understanding the Significance and Implications of Antibody Numbering and Antigen-Binding Surface/Residue Definition,” Front. Immunol. 9:2278, International Union of Immunological Societies, Ge…
[cited by applicant]
Rudinger, J.,
[cited by applicant]
Kranz, D.M., et al., “Restricted reassociation of heavy and light chains from hapten-specific monoclonal antibodies,” Proc. Natl. Acad. Sci. USA 78(9):5807-5811, National Academy of Sciences, United States (1981).
[cited by applicant]
Nezlin, R.S.,
[cited by applicant]
Maccallum, R.M., et al., “Antibody-antigen interactions: contact analysis and binding site topography,” J. Mol. Biol. 262(5):732-745, Elsevier, Netherlands (1996).
[cited by applicant]
Lamminmaki, U., et al., “Crystal structure of a recombinant anti-estradiol Fab fragment in complex with 17beta—estradiol,” J. Biol. Chem. 276(39):36687-36694, Elsevier, Netherlands (2001).
[cited by applicant]
Chen, C., et al., “Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations,” EMBO J. 14(12):2784-2794, European Molecular Biology Organ…
[cited by applicant]
ClinicalTrials.gov, “A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/Keynote-0036),” Identifier NCT02179918, retrieved from https://clinicaltrials.gov/ct2/show/NC…
[cited by applicant]
Office Action mailed May 17, 2022, in U.S. Appl. No. 16/335,971, Geuijen, C.A. W., et al., filed May 11, 2020, 20 pages.
[cited by applicant]
Morales-Kastresana, A., et al., “Combinations of immunostimulatory antibodies with synergistic effects against spontaneous cancer,” Oncoimmunology 3:e27812, Landes Bioscience, United States (Jan. 2014).
[cited by applicant]
Duraiswamy, J., et al., “Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer,” Cancer Res 73(23):6900-6912, American Association …
[cited by applicant]
Liu, X., “Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility,” Nature Communications 10:4206, Springer Nature, Germany (Sep. 2019).
[cited by applicant]